pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2929Research ArticleЛЕКЦИИLECTIONSЛевофлоксацин в ступенчатой терапии внебольничной пневмонии у взрослыхLevofloxacin in a gradual therapy of communtyacquired pneumonia in adultsСинопалъниковА. И.SinopalnikovA. I.Государственный институт усовершенствования врачей Министерства образования РФRussian Federation20022310202102116119Copyright © Синопалъников А.И., 20212021Синопалъников А.И.Sinopalnikov A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2929
.
ReferencesСтрачунский Л.C., Розенсон О.Л. Ступенчатая терапия: новый подход к применению антибактериальных препаратов. Клин, фармакол. и тер. 1997; 6: 15-24.Страчунский Л.C., Розенсон О.Л. Ступенчатая терапия: новый подход к применению антибактериальных препаратов. Клин, фармакол. и тер. 1997; 6: 15-24.Bartlett J.G. Respiratory tract infections. 3rd ed. Philadelphia: Lippincott W illiam s & W ilkins; 2001.Bartlett J.G. Respiratory tract infections. 3rd ed. Philadelphia: Lippincott W illiam s & W ilkins; 2001.Davis R., Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.Davis R., Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.File T.M., Sergeti J., Player R. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and /or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41: 1965-1972.File T.M., Sergeti J., Player R. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and /or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41: 1965-1972.Fine M.J., Auble T.E., Yealy D. M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. M ed. 1997; 336: 243-250.Fine M.J., Auble T.E., Yealy D. M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. M ed. 1997; 336: 243-250.Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 1997; 32: 101-119.Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 1997; 32: 101-119.Guidelines for the management of adults w ith communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.Guidelines for the management of adults w ith communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.Kahn J.B., Wiesinger A., Olson W.H. et al. Levofloxacin vs. ceftriaxone sodium and erythromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality [abstract P I 15]. In: Abstracts of 7th International Symposium on N ew Quinolones. Edinburgh, U K; 2001. 45.Kahn J.B., Wiesinger A., Olson W.H. et al. Levofloxacin vs. ceftriaxone sodium and erythromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality [abstract P I 15]. In: Abstracts of 7th International Symposium on N ew Quinolones. Edinburgh, U K; 2001. 45.Ramirez J.A. Switch therapy in community-acquired pnemonia. Diagn. Microbiol. Infect. Dis. 1995; 22: 219-223.Ramirez J.A. Switch therapy in community-acquired pnemonia. Diagn. Microbiol. Infect. Dis. 1995; 22: 219-223.
The authors declare that there are no conflicts of interest present.